Excision
San Francisco, United States · Founded 2015 · $60.0M raised
- Headquarters
- San Francisco
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Total Funding
- $60.0M
- Last Round
- $60.0M Series AFeb 2021
- Rounds
- 1
About
Excision BioTherapeutics is a biopharmaceutical company developing in vivo CRISPR-Cas9 and CRISPR-CasX gene-editing therapies designed to cure viral infectious diseases rather than merely suppress them. Its lead candidate, EBT-101, targets latent HIV-1 reservoirs and builds on gene-editing research originated in the lab of Temple University professor Kamel Khalili. The company received FDA fast-track designation for EBT-101 in 2023 and advanced the therapy into early-stage human clinical trials, though a 2024 readout showed it did not maintain viral suppression alone at the initial dose.
Summary
Excision is a Biotech company based in San Francisco, United States, founded in 2015. It has raised $60.0M in total across 1 round, most recently a $60.0M Series A round in Feb 2021. Investors include GreatPoint Ventures, Artis Ventures (AV) and Adjuvant Capital.
Funding History
Feb 2021
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/excision"><img src="https://indexed.vc/api/badge/company/excision" alt="Excision on Indexed.vc" width="260" height="76" /></a>